Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HOUSE BIOMEDICAL RESEARCH "ACCOUNTABILITY" BILL

Executive Summary

HOUSE BIOMEDICAL RESEARCH "ACCOUNTABILITY" BILL has 66 cosponsors. Rep. Torricelli's (D-N.J.) HR 560 would establish a new data center in the National Library of Medicine of full-text published literature on federally funded research. The purpose of the database is to avoid duplication in federal research projects using live animals. Among the cosponsors are five members of the House Energy & Commerce Committee: Jim Bates (D-Calif.); Jim Florio (D-N.J.); Edward Markey (D-Mass.); Cardiss Collins (D-Ill.); and Gerry Sikorski (D-Minn.). The bill has been referred to the committee, but no action has been scheduled. While the main purpose of the legislation is not to reduce the number of animals used in federally funded research, the bill does make an appeal to animal rights advocates. The bill points out, for example, that among the benefits of establishing the information storage and dissemination system is "the sparing of millions of laboratory animals from suffering, fear, and death in duplicative research." The animal rights movement has picked up momentum recently, although action has focused primarily on the cosmetics and household products industries. However, at least one group, the National Humane Education Society, specifically supports Torricelli's bill in a recent mailing to contributors. Under the legislation, introduced Jan. 19, all federally funded research proposals using live animals must be cleared through the new National Center for Research Accountability prior to approval. Torricelli's "Information and Research Accountability Act" directs the National Library of Medicine, "to the extent of funds appropriated for such purposes," to "acquire, in full-text form, all biomedical information owned by each Federal agency or available for use by Federal agencies" and to store all data available since 1960. The center would also make the information available at a cost to medical libraries. The National Library of Medicine is at the National Institutes of Health. According to Congressional Budget Office estimates, the cost of establishing the new center would be $ 38 mil. in the first year and a total of $ 200 mil. over the first five years. The estimates were developed last spring at Torricelli's request. HR 560 is identical to a bill introduced by Torricelli last August (HR 5154), but never acted upon. HR 5154 was a revised version of a bill introduced by the New Jersey Democrat earlier in the session. The earliest bill, HR 1708, contained an additional provision for the translation of foreign data collected by the new center. However, after CBO estimates suggested that the cost of translations would add significantly to the expense of implementing the bill, the clause was removed. No Senate versions of the legislation have been introduced.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS015430

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel